BD and Ypsomed Collaborate on 5.5mL Syringe to Enhance Self-Administration Efficiency
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Product Innovation: BD and Ypsomed's collaboration on the 5.5mL BD Neopak™ XtraFlow™ Glass Prefillable Syringe aims to meet the growing demand for large-volume subcutaneous injections, significantly enhancing patient self-administration convenience and efficiency.
- Technical Advantages: The new syringe features an 8mm short needle and thinner wall cannulas, enabling rapid injection of high-viscosity medications, which is expected to improve injection times and optimize flow, addressing common challenges associated with large-volume biologics.
- Market Demand Response: The launch of this product directly responds to the increasing demand for patient-friendly solutions in the high-dose biologics space, with BD and Ypsomed's partnership poised to drive market growth in high-dose biopharmaceuticals.
- Future Outlook: Syringe samples for feasibility studies are expected to be available by mid-2026, further integrating with Ypsomed's YpsoMate® 5.5 platform and assisting pharmaceutical companies in accelerating their product time-to-market.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 207.110
Low
183.00
Averages
202.38
High
220.00
Current: 207.110
Low
183.00
Averages
202.38
High
220.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
